Trials / Completed
CompletedNCT00640185
Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety, Tolerability and Efficacy of 40 mg QD and 80 mg QD ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-089 | Subjects will take up to two 40 mg tablets once daily for 8 weeks. |
| DRUG | Placebo | Subjects will take one or two placebos once daily for the duration of the study. |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2008-03-21
- Last updated
- 2013-01-18
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00640185. Inclusion in this directory is not an endorsement.